1. PRAGUE-18
Trial design: Patients with STEMI undergoing primary PCI were randomized to prasugrel (n = 634) versus ticagrelor (n = 596).
Results
(p = 0.94)
Death, reinfarction, urgent TVR, stroke, bleeding, or prolonged hospitalization at 7 days: 4.0% of the prasugrel group versus 4.1% of the ticagrelor group (p = 0.94)
CV death, nonfatal MI, or stroke at 30 days: 2.7% versus 2.5% (p = 0.86), respectively, for prasugrel versus ticagrelor
TIMI major bleeding at 30 days: 0.6% versus 0.7% (p = 0.85), respectively, for prasugrel versus ticagrelor
4.1
4.0 %
Conclusions
Among patients with STEMI undergoing primary PCI, similar efficacy and bleeding was observed for either prasugrel or ticagrelor. Among such patients, the use of either agent is acceptable.
Prasugrel
Ticagrelor
Motovska Z, et al. Circulation 2016;Aug 30:[Epub]